---
layout: post
title: "Human Prescription Drug and Biological Products-Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers-“Dose Banding”; Guidance for Industry; Availability"
date: 2026-02-05 18:57:04 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-21558
original_published: 2023-10-02 00:00:00 +0000
significance: 8.00
---

# Human Prescription Drug and Biological Products-Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers-“Dose Banding”; Guidance for Industry; Availability

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** October 02, 2023 00:00 UTC
**Document Number:** 2023-21558

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--`Dose Banding.' " The guidance is intended to assist applicants in incorporating dose banding information, based on dosing information of a previously approved drug product that is based on weight or body surface area (BSA), into the proposed labeling of injectable drug products that are the subject of certain marketing applications submitted to FDA. This guidance finalizes the draft guidance of the same title issued on July 21, 2022.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/10/02/2023-21558/human-prescription-drug-and-biological-products-labeling-for-dosing-based-on-weight-or-body-surface)
- API: https://www.federalregister.gov/api/v1/documents/2023-21558

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
